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Abstract
Background: Glioblastoma multiforme (GBM) is an umbrella designation that includes a heterogeneous group of primary
brain tumors. Several classification strategies of GBM have been reported, some by clinical course and others by
resemblance to cell types either in the adult or during development. From a practical and therapeutic standpoint, classifying
GBMs by signal transduction pathway activation and by mutation in pathway member genes may be particularly valuable
for the development of targeted therapies.
Methodology/Principal Findings: We performed targeted proteomic analysis of 27 surgical glioma samples to identify
patterns of coordinate activation among glioma-relevant signal transduction pathways, then compared these results with
integrated analysis of genomic and expression data of 243 GBM samples from The Cancer Genome Atlas (TCGA). In the
pattern of signaling, three subclasses of GBM emerge which appear to be associated with predominance of EGFR activation,
PDGFR activation, or loss of the RAS regulator NF1. The EGFR signaling class has prominent Notch pathway activation
measured by elevated expression of Notch ligands, cleaved Notch receptor, and downstream target Hes1. The PDGF class
showed high levels of PDGFB ligand and phosphorylation of PDGFRb and NFKB. NF1-loss was associated with lower overall
MAPK and PI3K activation and relative overexpression of the mesenchymal marker YKL40. These three signaling classes
appear to correspond with distinct transcriptomal subclasses of primary GBM samples from TCGA for which copy number
aberration and mutation of EGFR, PDGFRA, and NF1 are signature events.
Conclusions/Significance: Proteomic analysis of GBM samples revealed three patterns of expression and activation of
proteins in glioma-relevant signaling pathways. These three classes are comprised of roughly equal numbers showing either
EGFR activation associated with amplification and mutation of the receptor, PDGF-pathway activation that is primarily
ligand-driven, or loss of NF1 expression. The associated signaling activities correlating with these sentinel alterations
provide insight into glioma biology and therapeutic strategies.
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Introduction
Glioblastoma (GBM) is the most common malignant brain
tumor and is characterized by intratumoral heterogeneity, invasive
growth pattern and poor response to treatment.[1–4] While GBM
comprises approximately 25% of all brain tumors in adults, in
absolute numbers it is still an uncommon cancer. This low
absolute incidence combined with high morbidity, poor response
rates and short survival times pose practical problems for clinical
trial execution, particularly if therapy is anticipated to target a
molecularly-defined subset of tumors. The current first-line
treatment for GBM is radiation with alkylating chemotherapy
(Temozolomide) given concurrently and then continued after
radiation. This uniform first-line treatment approach contrasts
with the wealth of molecular data on mutations, genomic
aberrations and transcriptomal features in GBM which indicate
potential therapeutic targets and resolve apparently distinct
subclasses of these tumors.[3] We designed this investigation of
signal transduction pathway activation in GBM with the
expectation that tumor subclasses based on differential activation
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interpreting responses to therapies targeting these pathways, and
potentially applicable for stratifying patients in clinical trials.
Historically, two subtypes of GBM were distinguished based on
histologic grade at clinical presentation. Primary GBMs present
initially as grade 4 tumors while secondary GBMs present as lower
grade gliomas and progress to GBMs over time.[5] Although
primary and secondary GBM differ in the frequency of molecular
abnormalities seen, they draw largely from a common palette of
events: amplification and activating mutations in EGFR, over-
expression of PDGF and its receptors and loss of the tumor
suppressors INK4a/ARF, p53 and PTEN are well-documented,
recurrent mutations in these tumors.[1] Recent large-scale efforts
to characterize the glioblastoma genome have identified additional
recurrent alterations in genes not previously implicated in glioma,
such as ERBB2 and IDH1 mutation in primary and secondary
GBM respectively, and a significant incidence of mutation and
genomic loss of NF1.[6–8] While there is hope that further
sequencing will yield new therapeutic targets, it should be noted
that single-agent therapy trials of inhibitors directed to the two
most commonly altered receptors have not been successful in
unselected populations.[9,10] At least in some cases this may be
due to failure of RTK inhibition to impact downstream or parallel
signal transduction pathway activation.[11]
The importance of signal transduction activity downstream of
tyrosine kinase receptors in glioma biology is emphasized by the fact
thatthesepathwaysareabnormallyactiveinthesetumorsand causal
in their formation in mice.[12,13] Therefore, there is significant
interest in whether molecular subclasses of GBM might be identified
based on distinct signaling characteristics, and whether such
subclasses could be used to refine patient stratification in clinical
trials or help interpret treatment responses. Several studies have
subdivided GBMs by expression array analysis measuring total
cellular mRNA levels.[14–19] However, because of differential
translational efficiencies, total mRNA levels do not always correlate
with protein levels. Moreover, most signaling activity is achieved by
post-translational modifications of existing proteins such as Notch
cleavage, phosphorylation of kinases, or stabilization of proteins such
as beta catenin. To further complicate matters, signal transduction
activity may affect, through feedback mechanisms, the translational
efficiencies of mRNAs encoding proteins with effects on the
oncogenic phenotype.[20,21] Therefore, direct measurements of
active signaling components at the protein level are critical to fully
characterize the signal transduction state of the cell. Such
measurements have been made on glioma samples and have shown
correlation between the levelsof active pathway components.[20,22]
In this study, we have measured the relative protein levels of
signaling molecules within pathways thought to be crucial to
glioma biology among a panel of gliomas. This represents a more
extensive proteomic analysis of signaling pathway members than
has previously been done, and reveals three patterns of signaling
pathway activation. Distinct patterns were each associated with
EGFR and PDGF pathway activity while a third was associated
with low levels of NF1 protein. We present an analysis of genomic
features among tumors in each group, and show how these
proteomically-defined subclasses of GBM compare with genomic
subclasses arising from integrated analysis of primary GBM in data
from The Cancer Genome Atlas.
Results
Specimens and protein analysis
27 glioma surgical samples were identified from a database of
patients operated on at MSKCC and consented to the IRB-
approved protocol. Clinical and pathologic characteristics are
summarized in Table 1. Pathology included 20 GBM, 2 anaplastic
astrocytomas, 4 oligodendrogliomas of which 2 were anaplastic
tumors, and one tumor characterized as high grade glioma with
glioneuronal elements. 11 GBM were recurrent after treatment
(RT +/2 temozolomide) and two of these were secondary GBM.
The age range was from 32 to 74 (median 53).
Protein extracts from these tumors were analyzed by western blot
for the activity of various signaling pathways related to glioma
formation or stem cell character, totaling 55 antibodies for proteins
in total and active forms (Table S1). Antibodies were selected based
on known performance. Briefly, PDGF pathway activity was
measured by PDGF ligand (PDGFB), PDGFRa, PDGFRb and
phospho-PDGFRb. EGFR activity was assessed by antibodies
specific for EGFR and phospho-EGFR. The downstream pathways
interrogated included Ras, Akt, Notch, Wnt and SHH. The Akt
pathway was interrogated by PTEN, total AKT, phospho-AKT and
RHEB. Activation of mTOR was measured by phospho-S6
ribosomal protein (p-S6RP). The Ras pathway was interrogated by
BRAF and total/phospho-MEK and ERK. Notch pathway activity
was measured by the Notch ligands Delta (DLL1) and Jagged
(JAG1), full length Notch receptors 1 and 2, cleaved Notch 1 and 2
and downstream Notch target HES1. The Wnt pathway was
assessed bybetacateninlevelsand theSHH pathway bySHH levels.
NF1 was assayed in preserved lysates at a later date, after mutations
were reported for this gene in GBM.[7,8] Quantified bands for 55
antibodies were normalized against actin or tubulin. HEB, Notch1
and Notch2 antibodies each generated two bands which were
independently quantified. Therefore a total of 58 protein forms were
quantified and normalized. Relevant western bands selected by size
are summarized in Figure S1A, S1B, S1C, S1D, and quantified
values normalized against actin are given in Table S2A, S2B, S2C.
Principal Component Analysis and unsupervised
clustering identify three patterns of signaling in GBM
As expected, overall activation of signal transduction pathways
differed markedlybetween thegliomasamplesandthe normalbrain
reference. While some pathways such as PI3K and MAPK were
active nearly uniformly among gliomas, we sought to investigate
whether relative differences might distinguish subclasses among the
samples with GBM pathology. The overall pattern of protein
expression and activation wasfirst assessed by Principal Component
Analysis (PCA). Quantified western data for 57 protein forms were
standardized across the set of GBM samples for analysis (n=20).
We excluded p53 from analysis because common inactivating
mutations can be associated with increased or decreased protein
levels. For clarity in the figure, NF1 was represented as ‘‘NF1 loss’’
(zero minus standardized expression), reflecting the role of NF1 as
an inhibitor of RAS signaling. The first two PCA components
together accounted for the majority of variation in protein levels
(Figure S2). A cloud plot showing the first two principal components
is shown in Figure 1A and revealed three patterns of total and
activated protein levels. One component (PC2) distinguished
proteins which were correlated with EGFR total protein versus
those correlated with PDGFB levels. The other component (PC1)
distinguished a third group of proteins anti-correlated with EGFR
and PDGFB. Elevated levels of these proteins were associated with
low levels of Neurofibromin 1 protein (‘‘NF1 loss’’ in Figure 1A).
In order to evaluate the significance of this three-way classifica-
tion, we performed unsupervised k-means analysis on the same
standardized data from the 20 GBM samples and evaluated the fit
and stability over a range of cluster sizes. K-means for cluster sizes
from 2–8 was run for 10,000 iterations, leaving out 15% of the data
with each iteration (i.e. three randomly chosen samples left out).
Signaling Subclasses of GBM
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both visually and by cophenetic correlation (see Figure S3A). As
predicted from PCA, the correlation of protein levels was well-
described by 3-way clustering (Figure 1B). Considering only those
proteins which co-cluster in .95% of k-means iterations, three
‘‘core’’ protein groups were identified. These protein groups were
named according to the strong separation by PCA of EGFR, PDGF
and NF1 levels, with consideration that alterations in these three
genes are common in glioblastoma and each is pathogenic in
genetically-engineered mouse glioma models:
EGFR core. This cluster of 15 proteins features high levels of
total and phospho-EGFR. Prominent Notch activity is represented
in this group by high levels of the active cleaved form of Notch 1
(Notch 1 ICD) as well as of ligands Jagged (JAG1) and Delta-like 1
(DLL1) and of the downstream Notch transcriptional target HES1.
Wnt signaling is suggested by increased (stabilized) B-catenin
levels. Other proteins relatively increased in this core group are
EIF4EBP1, EIF4E, RHEB, phospho-BAD, INI1, La/SSB, FGF2,
and phospho-Rb1. There was a trend for higher phospho-Akt
levels, though this did not reach significance (p=0.08).
PDGF core. This cluster is comprised of 17 proteins including
PDGFB, phospho-PDGFRb and phospho-NFKB1. PTEN levels
are higher in this group and relatively increased Ras activity is
evidenced by elevated total and phosphorylated MEK and ERK.
Levels of MTOR and downstream targets S6K and p-S6K were
better-correlated with the PDGF core than the EGFR core,
though levels were high in tumors of both classes. Other PDGF-
associated proteins were SHH, HEB 1/2 (TCF12, associated with
oligodendrocyte development), BRAF, p-FOXO1 and TSC1.
NF1 Core. This group is defined by higher levels of 5
proteins: IRS1, IGFBP5, YKL40 and VEGF. As suggested by
PCA analysis, the group is also strongly associated with low levels
of NF1 (plotted as the inverse protein level, ‘‘NF1 loss’’). Sporadic
elevation of MYC, NMYC, and KRAS-GTP was also seen in this
group. Compared to the other classes, GBM samples showing
NF1-core expression pattern showed relatively suppressed levels of
total- and phospho-proteins in the PI3K and MAPK pathways.
These differences were relative, however, and evaluation of the
Western bands shows that high levels of phosphorylation were
common in nearly all tumors (see Figure S1).
Identification of proteomic tumor classes by signaling
pattern
The 44 core proteins identified in the previous analysis were
then used to cluster the larger set of 27 glioma samples. K-means
clustering of samples was performed as before, leaving out 15% of
Table 1. Patient and tumor characteristics.
ID Age M/F Survival (weeks) from resection Survival (weeks) from diagnosis Pathology Prior Treament
GBM.1 74 F 4 4 GBM –
GBM.2 66 F (6) (35) GBM RT
GBM.3 71 F 12 34 GBM RT
GBM.4 70 F 46 46 GBM –
GBM.5 39 M 32 45 GBM RT
GBM.6 67 F 150 150 GBM –
GBM.7 42 M 138 138 GBM RT
GBM.8 56 M 27 60 GBM RT + temozolomide
GBM.9 40 M 14 206 Secondary GBM PCV
GBM.10 52 M 35 35 GBM –
GBM.11 71 M 32 32 GBM –
GBM.12 53 F 5 44 GBM RT + temozolomide
GBM.13 47 M 35 38 GBM, oligoastrocytoma features –
GBM.14 59 M 21 47 GBM RT + temozolomide
GNT.15 68 M 51 69 High grade glioneuronal tumor RT
GBM.16 38 M 15 94 GBM RT
GBM.17 60 F 49 49 GBM –
GBM.18 32 F (3) (84) GBM RT, high dose thiotepa
GBM.19 49 M 85 85 GBM –
GBM.20 71 M 212 + 212 + GBM –
AO.21 64 F (218) (218) anaplastic oligodendroglioma –
ODG.22 52 F (6) (475) oligodendroglioma –
AA.23 46 F (76) (544) anaplastic astrocytoma high-dose thiotepa
AO.24 45 M 194 + 198 + anaplastic oligodendroglioma –
ODG.25 42 F 153 + 153 + oligodendroglioma –
AA.26 47 F 35 254 anaplastic astrocytoma RT
GBM.27 74 M 7 55 GBM RT + temozolomide
Demographic and pathologic description for 27 study patients. Survival is shown from time of resection of study tumor: ‘‘+’’ = still alive and parentheses mark patients
lost to follow-up. For recurrent tumors, prior treatment and survival from initial diagnosis.
doi:10.1371/journal.pone.0007752.t001
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this supervised approach, three-way clustering was the best fit and
all but three glioma samples showed stable clustering into signaling
classes associated with EGFR, PDGF and NF1-loss (Figure S3B).
Figure 2 summarizes how tumors are clustered by core signature
proteins, and how these groups relate to tumor histopathology and
genotype derived from aCGH profiling and resequencing of
EGFR.
Tumors with GBM histopathology were evenly distributed
among the three core groups, six in each group. The only known
secondary GBM clustered with the NF1-loss group. Two
anaplastic astrocytomas (AA23 and AA.26) were found to cluster
disparately with the PDGF and NF1 groups, respectively. Two of
the four oligodendrogliomas clustered with the PDGF group: one
low-grade (ODG.25) and one anaplastic (AO.24). Interestingly,
one of the two low-grade oligodendrogliomas clustered with the
EGFR group (ODG.22) and did in fact harbor high-level EGFR
amplification. One anaplastic oligodendroglioma (AO.21) showed
no distinct proteomic pattern and remained unclassified. There
was a trend for untreated tumors in the EGFR tumor group (6
untreated vs. 1 treated) and for treated tumors in the PDGF group
(3 untreated, 6 treated) but this was neither significant for GBM
(p=0.11) nor for all tumors (p=0.09). Testing protein levels
individually between treated and untreated GBM, PDGFB was the
most significantly different and was higher in treated GBM
(p=0.009) and in treated tumors overall (p=0.028) although
neither was significant after correction for multiple testing.
24 of the 27 tumors for which sufficient tissue was available were
analyzed by array-CGH (Agilent Whole Genome 244K) and
resequencing of EGFR, PTEN and TP53. Array-CGH profiles
were analyzed for copy number aberrations commonly described
in GBM: focal amplification of EGFR, MET and PDGFRA; gain of
chr7 without focal amplification; loss of chr10 or 10q23 region
spanning PTEN; loss and/or homozygous deletion of 9p21
including Ink4a/ARF.[1,23,24] Figure 2 summarizes the finding
of focal amplification of MET and EGFR, gain of chromosome 7,
homozygous deletion spanning the Ink4a/ARF locus, and loss at
PTEN locus. Complete ACGH profiles are depicted in Figure S4.
EGFR proteomic tumor class. Six of the seven tumors in
this class showed EGFR-region amplification and four showed
point mutations in the extracellular domain (ECD) previously
described in GBM as activating mutations: A289V (GBM.10 and
GBM.6), T263P (GBM.8), G598V (GBM.1) and R108K
(GBM.6).[25] The only tumor in the EGFR signaling cluster
that did not show focal EGFR amplification was found to harbor
amplification of a narrow region including MET. Neither
overexpression nor significant phosphorylation of EGFR protein
was seen in this case. All tumors in the EGFR proteomic tumor
class had deletion of the Ink4a/ARF locus compared with only 3/
17 (18%) in the other groups. All had loss of ch10 and mutation of
PTEN in the remaining allele was observed in one case.
PDGF proteomic tumor class. Although this group of
tumors is defined by evidence of PDGF signaling at the protein
level, none of the 9 tumors in this class showed gene amplification
of either PDGF receptors or ligands. One tumor had both Ink4a/
ARF region deletion and EGFR amplification, however total and
phosphorylated EGFR levels in this tumor were low and PDGFB
was present. Of note, a second tumor with focal MET
amplification, GBM.18, was classified here and showed
extremely high levels of PDGFB and associated signaling.
Figure 1. Analysis of quantified western data in 20 GBM identifies three signaling axes associated with EGFR overexpression,
PDGFB overexpression, and loss of NF1. (A) Principal component analysis (PCA) of 56 proteins in 20 GBM samples by quantified western blot
(see Methods). The first two components are plotted, accounting for 51% of variance in protein levels. PC2 strongly distinguishes proteins correlated
with EGFR (red arrow) versus PDGFB (blue), while PC1 distinguishes a third pattern which is correlated with neither of these RTK pathways. Of note,
NF1 appears to be silenced in this group (‘‘NF1 loss’’, zero minus standardized protein expression, green). Dashed lines bound proteins with
significant co-expression by k-means clustering (see B). Inset shows the western bands confirming mutual exclusivity for EGFR expression, PDGFB
expression and NF1 silencing. (B) K-means clustering of proteins confirms three statistically significant core clusters. Unsupervised k-means clustering
of quantified protein levels in 20 GBM reveals 3 patterns of coordinate protein expression. The consensus matrix shown represents how often two
proteins were co-clustered during 10,000 iterations, leaving out 15% of samples (n=3) selected at random for each iteration. ‘‘Core’’ correlated
proteins are those that show .95% co-clustering across iterations (dashed-lines). These define an EGFR group, a PDGFB group and a third non-EGFR/
PDGF group which features NF1 loss. 3-way clustering was determined to be the best fit by consensus matrix stability and cophenetic correlation (see
text, Figure S2).
doi:10.1371/journal.pone.0007752.g001
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six GBM, one of which was a secondary GBM, one anaplastic
astrocytoma, and one tumor with histopathologic features of GBM
and synaptophysin positivity (‘‘glioneuronal tumor’’, GNT.15).
The NF1-associated class is distinguished by chr7 gain without
focal amplification of either EGFR or the MET receptor which is
significantly more frequent in this class (5/7, 71%) compared to
the others (2/14, 14%, p=0.017, Fisher’s Exact test).
Integrated analysis of molecularly defined subclasses of
GBM from The Cancer Genome Atlas identifies distinct
tumor subclasses enriched for mutations in EGFR,
PDGFRA, and NF1
Glioblastoma datasets from The Cancer Genome Atlas were
analyzed for alterations in EGFR, PDGFRA and NF1 and the
possible association of mutations in these genes with transcripto-
mally-defined subclasses. Of 278 tumors for which chromosomal
copy number and/or mutation data were available, amplification
and/or somatic non-synonymous mutation of EGFR was found in
40% (n=111) and of PDGFRA in 7% (n=19), while chromosomal
loss and/or mutation of NF1 was found in 16% (n=45). As shown
in Figure 3, genomic alterations in these three genes are largely
mutually exclusive, suggesting distinct tumor subclasses among this
portion of GBM samples for which clear genomic alterations could
be detected.
We next sought to determine if these subclasses might be
associated with distinct transcriptomal signatures. Using normal-
ized gene expression profiles on 243 tumors downloaded from The
Figure 2. K-means clustering of gliomas by signature-defining proteins. Unsupervised k-means clustering of 27 gliomas by 44 core proteins
derived from Figure 1B. 3-way clustering was determined to be the best fit by consensus matrix stability and cophenetic correlation (Figure S3). Right:
summary of array-CGH, sequencing and clinical information is given for each tumor. Red denotes copy number gain or focal amplification as
specified; green marks deletion of at least one copy. Blue denotes mutations (see text). Gray marks samples for which DNA was unavailable. Detailed
aCGH profiles shown in Figure S4.
doi:10.1371/journal.pone.0007752.g002
Figure 3. Integration of mutation and chromosomal copy
number data from TCGA reveals aberrations of EGFR to be
mutually exclusive of aberrations in PDGFRA and NF1. Summary
of copy number aberrations (CNA) and mutations of EGFR, PDGFR and
NF1 genes in 278 glioblastoma samples from The Cancer Genome Atlas.
163 samples showed mutation/aberration of at least one of the genes.
For this summary, only validated, non-synonymous somatic mutations
were considered (164/278 samples had sequencing information
available). CNA was defined as focal high-amplitude amplification (.4
copies) of EGFR or PDGFR, and by at least single-copy loss of NF1.
doi:10.1371/journal.pone.0007752.g003
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hierarchical clustering which identified 4 main cluster branches
(Figure 4). This grouping was concordant with comparable 4-way
cluster structure recently reported by the TCGA.[26] Integration
of copy number aberration, mutation and expression of EGFR,
PDGFRA and NF1 revealed that three of the transcriptomal classes
were enriched for alterations in each gene, respectively, although
the segregation was imperfect. We named these three subclasses
‘‘EGFR cocluster’’, ‘‘PDGFRA cocluster’’ and ‘‘NF1 cocluster’’
based on the predominant signal transduction pathway member
enriched for mutation in each group. A fourth transcriptomal class
had neither significant enrichment for mutations in either of
EGFR, PDGFRA or NF1, nor enrichment for mutations in any
other sequenced gene in the TCGA dataset. As shown in Figure 4
as described below, PDGFRA amplification was only present in the
minority of PDGFRA-cocluster tumors and this transcriptomal
class included a subset of tumors with EGFR or Met amplifica-
tions. The PDGFRA-cocluster showed high expression of GRIA2,
OLIG2, and NCAM1/2 as well as other genes which are signatures
of the ‘‘Proneural’’ transcriptomal class of GBM previously
described.[19] Conversely, signature genes of the ‘‘Mesenchymal’’
GBM class such as YKL40/CHI3L1, IGFBP2 and VEGFA were
most highly expressed in the NF1-cocluster transcriptomal group
(Figure S5). The EGFR-cocluster class showed intermediate
expression levels of Proneural and Mesenchymal signature genes.
Unsupervised clustering reflects the combined effect of multiple
confounding influences on the transcriptome, including presence
of necrosis, inflammatory cells, inclusion of brain parenchyma, etc.
In order to clarify the specific relationship of EGFR, PDGFRA and
NF1 mutations to the transcriptome in GBM, we derived distinct
expression signatures associated with mutation/aberration of these
genes among the set of 147 tumors for which mutation/aberration
was found in one and only one of the three. Together, 1,943 genes
were identified which distinguished the three mutation classes (see
Methods). Hierarchical clustering performed with this gene set on
the full set of 243 GBM profiles resulted in clear division of GBM
into just 3 subclasses, each enriched for the associated alteration of
EGFR, PDGFRA and NF1 (Figure S6).
Comparison of proteomic and transcriptomal subclasses
We investigated possible correspondence between the proteo-
mic EGFR, PDGF and NF1 classes and the transcriptomal
EGFR-, PDGFRA-, and NF1-coclusters derived from TCGA data
by comparing signature genomic aberrations. As shown in
Figure 4, integration of mutation and copy number data
confirmed the strong association of EGFR amplification and
mutation in tumors from the EGFR-cocluster (59/79, 75%)
significantly more than in the other two classes (21/99, 21.2%,
p=7.8e213). This subset of samples also harbored frequent
homozygous deletion of 9p21 spanning the Ink4a/ARF locus (75%
vs 35%, p=2.0e27). These findings were concordant with
genomic profiling of tumors the EGFR signaling class. Conversely,
chr7 gain without focal amplification of either EGFR or MET was
most common in the NF1 transcriptomal cocluster (60.7% vs 23%,
p=1.6e26), and this was concordant with aCGH profiling of
tumors in the NF1 signaling class.
Among TCGA samples, amplifications of PDGFRA were more
commonly seen in the PDGFRA transcriptomal cocluster (25.6%
Figure 4. Unsupervised transcriptomal clustering of GBM from the TCGA dataset. Unsupervised hierarchical clustering of gene expression
from 243 GBM samples in The Cancer Genome Atlas reveals four transcriptomal clusters, three of which are enriched for alterations of PDGFRA, NF1,
and EGFR respectively. Expression data is from Affymetrix U133A and copy number is taken from Agilent 244K platform (TCGA Level 3 public data, see
Methods). Gene expression for EGFR, PDGFRA, and NF1 is shown in the bar plots, colored according to gene copy number: amplification (red) or loss
(green). Blue boxes denote samples with non-synonymous somatic mutations which have been validated (solid) or are pending validation (open).
Three clusters are highlighted which show specific enrichment for lesions in genes encoding key signal transduction pathway members EGFR,
PDGFRA and NF1. A fourth cluster lacks clear enrichment for any specific mutation or CNA.
doi:10.1371/journal.pone.0007752.g004
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(3/29=10.3% vs 0/79, p=0.049). However 4 out of 5 MET-
amplified tumors were in this class and 7 tumors showed focal
amplification of EGFR. Therefore there was no single copy
number aberration distinguishing this class. There were no cases of
PDGFRA amplification among the 24 tumors in our study for
which aCGH was performed. Among the 9 tumors in our PDGF
signaling class, one had MET amplification and one had EGFR
amplification. Despite the absence of PDGFRA-amplified cases in
our sample set, the overall distribution of EGFR, PDGFRA and
MET amplifications was found to be within the normal sampling
error if one derives expectation frequencies from the TCGA data.
Comparison of genomic aberrations suggested a correspon-
dence between proteomic classes of EGFR, NF1 and PDGF and
the corresponding TCGA transcriptomal classes, therefore
expression levels for genes encoding the core proteins (total forms)
were next assessed in each of the four transcriptomal clusters.
Among genes encoding EGFR-core proteins, the corresponding
EGFR transcriptomal cocluster subclass showed significant
overexpression of EGFR, JAG1, and HES1 compared to the other
subclasses (p,1e25 for each gene). However other EGFR core
proteins and Notch pathway members showed no elevation of
mRNA expression in the corresponding transcriptomal class and
therefore direct correlation could not be established.
Within the transcriptomal NF1-cocluster, the only overex-
pressed genes encoding NF1 core proteins were IRS1 and YKL40/
CHI3L1. As seen in Figure 4, NF1 mRNA was strongly
underexpressed in the NF1-cocluster class compared to other
classes (p=4.4e215), making NF1 mRNA underexpression
among the strongest signatures of the transcriptomal class.
Within the PDGFRA transcriptomal cocluster, TSC2 and HEB/
TCF12 were the only genes among the PDGF core protein group
significantly overexpressed (p,1e24). The PDGFRB gene was
significantly underexpressed in this group, concordant with our
observation that total protein levels were higher in the EGFR class
even while the phosphorylated receptor was correlated with the
PDGF class. Overexpression of PDGFRA was a prominent feature
of the PDGFRA-cocluster tumors (p,1e212), nearly always
associated with gene amplification. Messenger RNA levels of genes
encoding PDGF ligands were not elevated in the PDGFRA
cocluster even among the subset of tumors showing PDGFRA
amplification. We further investigated the relationship of PDGFB
mRNA and protein levels in a validation set of 40 gliomas and
found no correlation between mRNA expression and levels of
protein even though the latter were highly variable (Figure S7).
This reflects the strong regulation of PDGF at the level of
translation rather than transcription.[27,28] It is likely that some
signaling proteins in our study are closely coupled to mRNA levels
while many others are regulated independently (or in negative
feedback) with corresponding mRNA.
Discussion
Given the importance of signaling in the biology of gliomas,
dividing these tumors into subsets by the pattern of coordinate
signaling pathway activation may have practical implications for
choice of therapies and for interpretation of patient responses in
existing clinical trials. In order to clarify the net activation of
signaling pathways we used a targeted proteomic analysis to
determine not only the levels but the posttranslational modifica-
tions associated with signaling activity. The intrinsic cellular
heterogeneity of gliomas is masked by the methods used in this
study since both the proteomic and TCGA genomic analyses are
performed on homogenized tissue, blending the characteristics of
the cells together. Additionally, the small sample size and selection
of proteins in this study limits the statistical power to define protein
correlations and sample assignments. Nonetheless, we find
common features defining three basic groups by both genomic
and protein analysis, illustrating the high complementarity
between protein signaling activity, transcriptomal signature and
genomic alteration in GBM. The observed enrichment of EGFR,
PDGFRA and NF genomic alterations with transcriptome pattern
could mean that signaling activity directly influences the
transcriptome and/or that both signaling and the transcriptome
patterns are part of a common underlying phenotype. Comparing
unsupervised and supervised clustering results, it is likely that only
a portion of the transcriptomal features distinguishing unsuper-
vised clusters are associated with signaling, either directly or
indirectly. In fact, unsupervised clustering identifies four clusters
and broader phenotypic and genetic differences distinguishing
these four transcriptomal groups have been reported.[26]
Analysis of the downstream signaling components of the PDGF
proteomic group revealed generally lower PI3K/Akt activity than
in the EGFR glioma group although S6 phosphorylation was
paradoxically high. Histologic analysis of the tumors provided an
explanation by demonstrating that strong pS6 immunopositivity
was localized in reactive astrocytes rather than tumor cells per se
(data not shown), concordant with recent observations of mTOR
activation in reactive astrocytes under experimental conditions of
injury.[29] These cells were more common in PDGF-class tumors.
We found a trend for treated tumors to be in the PDGF proteomic
class and PDGFB levels were significantly higher in treated
compared to untreated tumors. It is possible that some of the
features of the PDGF signaling pattern are influenced by prior
treatment though it is unlikely that this accounts for the genotypic
differences in this proteomic tumor class, such as the paucity of
EGFR amplification, chr7 gain and Ink4a/ARF locus deletion.
Comparison with treated samples in TCGA is complicated by the
fact that the current dataset contains few treated cases and of
these, many are secondary GBM which would arguably be
assigned to the PDGFRA co-cluster by their common Proneural
signature.
The histology of the TCGA samples was uniformly GBM, but
this is a histologically heterogeneous tumor type. A priori, it is
possible that the transcriptomal classes identified in this analysis
could be related to tumor sampling or microenvironment.
However, this does not appear to be the case since well-defined
genetic lesions are enriched in specific tumor classes and there is
no evidence for regional localization of mutations in glioma as a
general phenomenon. Although clinical and pathologic data are
limited and a more detailed review of this information is
underway, there appeared little clinical or histological differences
between the three groups identified in this analysis. PDGFRA-
cocluster tumors in TCGA occurred in younger patients, and
there were small but significant differences in the amount of
associated necrosis and inflammatory cells (data not shown).
It remains to be established whether ligand-driven PDGF
signaling is common among tumors in the transcriptomal
PDGFRA-cocluster and whether this is functionally important.
We have shown that PDGFB ligand levels are highly variable in
GBM, are associated with receptor activation, and are not
correlated with mRNA expression. The PDGFRA-cocluster
transcriptomal class shares features with the Proneural group of
gliomas identified by Phillips et al using transcriptionanalysis, and is
characterized by genes expressed during normal cortical oligoden-
drocyte development such as olig2, Sox2 and doublecortin and
signaling pathways involved in that process as well, such as PDGF
and SHH. While the PDGFRA-cocluster group is enriched for
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signature was derived from a dataset of mixed histologies and the
analysis designed specifically to resolve a prognostic signature.
Therefore the exact relationship between our PDGF proteomic
class, the PDGFRA co-cluster, and gliomas harboring Proneural
signature is unclear and will need to be further investigated.
Although PDGFRA amplification predominated in the
PDGFRA-cocluster transcriptomal group, a full 15% showed
amplified EGFR and another 15% showed amplified MET. From
the prevalence of PDGF signaling we found at the protein level
one might hypothesize the existence of concurrent PDGF signaling
in EGFR- and MET- amplified tumors in this class. In fact, we
found two such tumors in our proteomic analysis: one EGFR- and
one MET-amplified, both with high levels of PDGFB, phosphor-
ylation of PDGFRb and an overall signaling pattern matching the
PDGF proteomic class. It is unclear in these cases whether the
level of PDGF pathway activation is functionally important,
perhaps in a subpopulation of cells. It is notable that 6 tumors in
TCGA show focal amplification of both PDGFRA and another
RTK: four cases sharing focal co-amplification of EGFR, and two
cases sharing focal co-amplifications of PDGFRA and MET.
In conclusion, our findings support a division of GBMs into
three classes according to patterns of signal transduction pathway
activation. These patterns reflect, in part, mutually exclusive
signaling involving EGFR, PDGF RTK activation or NF1
silencing. Both the transcriptomal and proteomic classes were
imperfectly related to genotype, suggesting that molecular assays
used in patient stratification and clinical trial analysis should
include measures of PDGF ligand and receptor phosphorylation as
well as NF1 expression. Notch signaling was prominently
associated with the EGFR class at the protein level, an observation
which was not predicted by mRNA expression levels of Notch
pathway members in EGFR-altered tumors from TCGA.
Whether one or more non-EGF/PDGF RTKs are contributing
to NF1 tumors is uncertain, but the finding that NF1-silenced
tumors show elevated MET, HGF and IRS1 at the transcriptomal
level and validation of IRS1 at the protein level suggest IGF and or
MET signaling may be contributory. Further refinement of GBM
subclasses will likely come from direct investigations of these and
other signaling proteins, as well as investigation of newly described
recurrent mutations in GBM such as ERBB2 and IDH1. The
current study provides an initial architecture for such subclasses
and suggests the potential for class-directed therapies.
Methods
Ethics statement
The collection and use of the human tissues in this study were
performed after obtaining written consent from all participants, in
accordance with a study protocol approved by the Institutional
Review Board of Memorial Sloan-Kettering Cancer Center. Data
from The Cancer Genome Atlas public portal were obtained
under an approved Data Access Request.
Surgical glioma sample analysis
Tumor samples. Tumors were snap-frozen in the operating
room, and stored at 280uC. Samples in liquid nitrogen were
ground to powder and protein was extracted through lysis with T-
per tissue extract solution (Pierce) supplemented with 30 mM
sodium fluoride, 1 mM sodium vanadate, and protease inhibitor
cocktail tablets (Roche). Protein concentrations were determined
by bicinchoninic acid assay (BCA) method (Bio-Rad).
Western blot analysis. Samples (100 mg) were separated by
6, 8, 10, or 12% SDS-PAGE gel, and transferred onto
polyvinylidene difluoride membrane (Millipore). For qualitative
comparison, analysis included normal brain cortex lysate as
previously described (Analytical Biological Services Inc).[30]
Membranes were blocked with 5% nonfat milk in PBS-0.1%
Tween 20. Primary and secondary antibodies were diluted in the
blocking solution. Signal was visualized using enhanced
chemiluminescence (Amersham Biosciences). Primary antibodies
used in this study are listed in Table S1. Secondary peroxidase-
conjugated anti-rabbit antibody (Amersham Biosciences), anti-
mouse and anti-goat antibodies (Roche) were used at 1:1,000
dilution. For NF1, 50 ug of lysate was run on 6% gel and
secondary antibody was 1:10,000 dilution. PDGFRa total protein
was assayed at a later date by western blot of frozen banked lysate
aliquots (Santa Cruz, #sc-338, 1:500, secondary 1:10,000).
Because of low band intensity a second PDGFRa antibody was
tested as well and gave concordant results (Cell Signaling #3174,
1:1000, secondary 1:2,000). The density of each band was read
and quantified using Adobe Photoshop and NIH Image 1.63
software and normalized by actin control. PDGFRa western was
normalized to tubulin.
Activated ras pull-down assay. Activated K-ras (K-ras-
GTP) was tested by using 500 mg samples for activated Ras pull-
down with 10 mg of glutathione-conjugated Raf-1 GST-RBD
beads (Upstate Biotechnology) as previously described.[31]
Unsupervised clustering of protein data. Quantified
western data were standardized for each protein by mean and
standard deviation across the sample cohorts. Standardization was
done first on the glioblastoma samples (n=20) for unsupervised
clustering analysis of protein level, then again separately on the
whole sample set (n=27) for cluster analysis of samples. For the
purpose of display, NF1 is represented as ‘‘NF1-loss’’, or zero
minus standardized NF1 quantity on western. All statistical
analyses and plotting were done in R (www.cran.org). Principal
component analysis was performed on standardized data. K-
means clustering of quantified protein levels for 20 GBM samples
was performed in R, and stability of cluster assignment assessed
over 10,000 iterations leaving out 15% of tumors with each
iteration (kmeans, stats package, www.cran.org). Consensus
matrices were generated for each k-clustering over all iterations
and assessed visually as well as by cophenetic correlation. Core
correlated protein clusters are defined for 3-way clustering as
.95% consensus. Proteins in these core clusters were selected for
k-means analysis of 27 gliomas using, as before, an 85%
resampling of proteins and consensus matrix analysis over
10,000 iterations.
ACGH and resequencing. Genomic DNA was extracted
from primary tumors using standard techniques. DNA was then
digested and labeled and hybridized to 244K CGH arrays
according to manufacturer guidelines (Genomic DNA labeling
kit PLUS, Agilent). This array consists of .238,000 coding and
non-coding sequences allotted to assembly map positions (NCBI,
Build 35). Normal male genomic DNA (Promega, Madison, WI)
was used as a reference. After washing, the slides were scanned
with an Agilent scanner and images quantified using Feature
Extraction 9.5.3.1 (Agilent). Fluorescence ratios of the scanned
images were calculated and the raw aCGH profiles were processed
to identify statistically significant transitions in copy number using
the Circular Binary Segmentation algorithm.[32] Each profile was
centered so that log2 ratio of zero is assigned to the predominant
copy number, determined by the mode of the distribution of the
mean log2 ratio for each segment, weighted by the number of
probes per segment . After mode-centering, gains and losses for a
subset of analyses were defined as segment mean log2 ratios of
.0.2 or ,20.2 and amplification and deletions as .2o r,21,
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alterations were computed for all other analyses. The annotated
microarray data for the sample set is available on GEO (www.
ncbi.nlm.nih.gov/geo, GSE17381).
Integrated analysis of genomic data from The Cancer
Genome Atlas
Dataset compilation and analysis. A description of TCGA
data types, platforms and analyses are as previously described.[8]
Processed genomic datasets were downloaded from The Cancer
Genome Atlas public data portal (http://cancergenome.nih.gov/
dataportal/) as available on May, 2009. Specific data sources were
as follows: For mRNA expression, ‘‘Level 3’’ normalized gene
expression derived from the Cancer Genome Characterization
Center (CGCC) at the Broad Institute, MIT (Affymetrix Human
Genome HTS U133A 2.0). For chromosomal copy number,
‘‘Level 3’’ normalized and segmented copy number data from the
CGCC at Memorial Sloan-Kettering Cancer Center (Agilent
244K CGH Array). From this array-CGH dataset one unique
profile was selected for each tumor based on the highest
signal-to-noise estimate. For sequencing data, we combined all
available sequencing data summaries in ‘‘multiple alignment
format’’ (MAF) files as of May 2009: broad.mit.edu GBM.ABI.1,
genome.wustl.edu GBM.ABI.53, hgsc.bcm.edu GBM.ABI.1.maf
and GBM.ABI.2. Mutations were further filtered by excluding
events which were classified as ‘‘somatic,’’ ‘‘synonymous’’ or
‘‘silent,’’ or ‘‘unvalidated,’’
A list of the sample IDs and the summary of genomic data are
given inTable S3. 243 samples had gene expression from Affymetrix
U133A platform. Of these, 237 also had aCGH data and 159 had
mutation data available. Level 3 array-CGH data was used for local
copy number estimation. Amplification was defined by regional log2
ratio .2.0. Gene loss was classified by minimal log2 ratio (log2R)
across the gene as follows: ‘‘single copy loss’’=21.0,log2R,20.2;
‘‘homozygous deletion’’=log2R,21.0.
Clustering of TCGA expression dataset. Unsupervised
clustering of TCGA Level 3 expression data was performed on
1,807 genes representing the top 15%ile of variance (hierarchical
clustering, correlation metric, complete linkage; hclust, R
package:stats,). Supervised cluster analysis was performed as
follows: 147 samples were identified harboring only one of either
EGFR mutation/amplification (n=103), PDGFRA mutation/
amplification (n=14) or NF1 mutation/loss (n=30). Kruskal-
Wallis (kruskal.test, R package:stats) test was used to identify genes
which discriminate between EGFR-, PDGFRA- and NF1-altered
samples. Because only 14 samples in TCGA set harbor solitary
PDGFRA alteration, the numbers of profiles in each class are
balanced by sampling 14 of the 103 EGFR-altered and 14 of the
30 NF1-altered samples and the KW test is run iteratively 1000
times with resampling. 1,953 genes were found to show KW p-
values ,0.05 in .95% of iterations and these were used to
perform supervised hierarchical clustering. Calculation of
significance for differences between cluster was by Fisher’s Exact
Test (R package:stats) using cluster assignments for PDGFRA,
NF1 and EGFR-coclusters derived from unsupervised clustering,
and excluding samples belonging to the ‘‘Indeterminate
Genotype’’ cluster.
Supporting Information
Figure S1 Selected bands from western blots which were
quantified in this study. Signaling class assignments are shown
for those samples with stable clustering: ‘‘P’’= PDGF class,
‘‘N’’=NF1 class, and ‘‘E’’=EGFR class.
Found at: doi:10.1371/journal.pone.0007752.s001 (6.30 MB TIF)
Figure S2 Principal Componenet Analysis of Quantified Protein
Levels: Fractional variance for principal components from the
analysis of quantified protein levels in 20 GBM samples. The first
two components together account for 51% of total variance and
are plotted in Figure 1A.
Found at: doi:10.1371/journal.pone.0007752.s002 (0.34 MB TIF)
Figure S3 Analysis of stable cluster assignment by k-means for
varying cluster count: K-means clustering of quantified and
standardized protein levels in GBM; classification of gliomas by
core protein expression patterns. For each analysis, K-means was
run for 10,000 iterations leaving out 15% of data with each
iteration. Shown are consensus matrices for division into 2–4
clusters, and cophenetic correlations for division into 2–8 clusters.
(A) Clustering of 55 proteins in 20 GBM samples shows stable two-
way and three-way clustering with peak cophenetic correlations
,0.98. Details for 3-way clustering are shown in Figure 1B in the
main text. Three sets of ‘‘core’’ proteins (n=46 total) are defined
by their stable cluster membership in .95% of iterations. (B) 27
glioma samples clustered by 44 core proteins identified in the
preceding analysis and highlighted in Figure 1B. Gliomas are
classified into 3 types based on the levels of 44 total and activated
protein forms.
Found at: doi:10.1371/journal.pone.0007752.s003 (1.04 MB TIF)
Figure S4 Genomic profiling of gliomas clustered by signaling
class: Array-CGH shows high concordance between EGFR
signaling class and amplification of EGFR locus and deletion of
the Ink4a/ARF locus. Tumors in the NF1 class show frequent gain
of chr7 without focal amplification of either EGFR or MET. Of
the two tumors which do have focal MET amplification, one
clusters with EGFR-class and the other with PDGF-class. No
amplification of PDGFRA was found in any of the samples.
Found at: doi:10.1371/journal.pone.0007752.s004 (0.96 MB TIF)
Figure S5 Expression of Proneural and Mesenchymal signature
genes in transcriptomal subclasses: Expression analysis of Pro-
neural and Mesenchymal signature genes across transcriptomal
subclasses derived from The Cancer Genome Atlas. Unsupervised
clustering of TCGA samples and subclass assignments are as
shown in Figure 4. Tumor profiles in each subclass are assessed for
enrichment of signature genes defining the Proneural and
Mesenchymal transcriptomal classes of GBM previously described
[19]. Box plots show the distribution of mean percentile rank for
expression of Proneural and Mesenchymal signature gene sets
courtesy of Kenneth Aldape, MD: Proneural= BMP2, GRIA2,
OMG, NCAM1&2, OLIG2, BCAN, RTN1, SNAP91,
GABBR1&2, and KCNB1; Mesenchymal= YKL40/CHI3L1,
IGF2BP3, VEGFA, COL1A1, COL5A2, COL3A1.
Found at: doi:10.1371/journal.pone.0007752.s005 (0.35 MB TIF)
Figure S6 Supervised transcriptomal clustering of GBM tumors
in The Cancer Genome Atlas: Clustering of 243 GBM samples
form TCGA using ,1,900 genes selected for their ability to
discriminate three genotypes: EGFR mutation/amplification,
PDGFRA mutation/amplification or NF1 mutation/deletion (see
Methods). Sample set and figure legend are as shown in Figure 4
and clustering methods differ only in the subset of genes used.
Samples are clustered into three divisions each enriched for one of
the three genotypes.
Found at: doi:10.1371/journal.pone.0007752.s006 (0.91 MB TIF)
Figure S7 PDGFB protein levels are not correlated with mRNA
expression: PDGFB protein levels were assessed in a validation
panel of 40 gliomas by western blot and compared with mRNA
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variable amounts there is no correlation with mRNA, concordant
with post-transcriptional regulation of PDGF.
Found at: doi:10.1371/journal.pone.0007752.s007 (0.77 MB TIF)
Table S1 Antibodies and conditions used for western blot panel.
Antibody sources and conditions as shown. *Hes1 antibody kindly
provided by Dr. Tetsuo Sudo (Toray Scientific, Japan).
Found at: doi:10.1371/journal.pone.0007752.s008 (0.03 MB
XLS)
Table S2 Quantified western results. Western bands quantified
by densitometry and normalized to actin (see Methods). Images of
selected bands are shown in Figure S1.
Found at: doi:10.1371/journal.pone.0007752.s009 (0.05 MB
XLS)
Table S3 Summary of integrated analysis of genomic data from
278 samples in The Cancer Genome Atlas. In this table, mutations
are denoted in blue and designated ‘‘validated’’ and ‘‘unvalidated’’
according to whether TCGA reports that the mutation was
verified by second sequencing method or whether such verification
is pending. Focal amplifications in red and single-copy loss or
homozygous deletion (light and dark green, respectively) are
inferred from array-CGH log2 ratios (see Methods). Cluster
assignments are derived from Figure 4.
Found at: doi:10.1371/journal.pone.0007752.s010 (0.08 MB
XLS)
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